A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Irinotecan and Its Metabolite SN-38 When Coadministered With Folinic Acid and 5 Fluorouracil in Patients With Advanced Malignant Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Ramucirumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 25 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 16 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 05 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.